CMO urges caution over one vax dose for Indian strain
More real-world data is needed on the effectiveness of a single coronavirus vaccine dose against variant B617, says Professor Paul KellyÂ
Australia’s Chief Medical Officer is wary of a study showing a single dose of Pfizer or AstraZeneca vaccine is only 33% effective against the Indian COVID-19 strain.
Professor Paul Kelly has warned the research is yet to be peer reviewed, and that real-world data will be needed to determine how effective one dose of the nation’s vaccines are against the so-called Indian coronavirus strain, or variant B617.
Melbourne is in the midst of an outbreak of the variant, which has infected more than 50 people and plunged Victoria into lockdown.
A Public Health England study found last month two doses of AstraZeneca and Pfizer were 88% effective against the strain.
